Ipilimumab in the treatment of advanced melanoma – a clinical update

Bibliography

• Trinh VA, Hwu WJ. Ipilimumab in the treatment of melanoma. Exp Opin Biol Ther 2012;12:773-82
   PubMed Web of Science ®Google Scholar
• Yervoy® (Ipilimumab) US prescribing information 2013. Bristol-Myers Squibb, Princeton, NJ. Available from: http://packageinserts.bms.com/pi/pi_yervoy.pdf [Last accessed 6 April 2014]
   Google Scholar
• YERVOY™ (ipilimumab) Summary of Product Characteristics. Bristol-Myers Squibb, Uxbridge, UK. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf [Last accessed 6 April 2014]
   Google Scholar
• Zelboraf® (Vemurafenib) US prescribing information 2014. Genentech USA, Inc. South San Francisco, CA. Available from: www.gene.com/download/pdf/zelboraf_prescribing.pdf [Last accessed 6 April 2014]
   Google Scholar
• Tafinlar® (Dabrafenib) US prescribing information 2014. GlaxoSmithKline, Research Triangle Park, NC. Available from: http://us.gsk.com/products/assets/us_tafinlar.pdf [Last Accessed 6 April 2014]
   Google Scholar
• Mekinist® (Trametinib) US prescribing information 2014. GlaxoSmithKline, Research Triangle Park, NC. Available from: http://us.gsk.com/products/assets/us_mekinist.pdf [Last Accessed 6 April 2014]
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
   PubMed Web of Science ®Google Scholar
• McDermott D, Haanen J, Chen TT, et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 2013;24:2694-8
   PubMed Web of Science ®Google Scholar
• Maio M, Bondarenko I, Robert C, et al. Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma [abstract 3704]. Presented at: European Cancer Congress 2013; 27 September – 1 October 2013; Amsterdam, Netherlands
   Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [abstract LBA24]. Presented at: European Cancer Congress 2013; 27 September – 1 October 2013; Amsterdam, Netherlands
   Google Scholar
• Robert C, Schadendorf D, Messina M, et al. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013;19:2232-9
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines—Melanoma. V4.2014. Available from: www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf [Last accessed 29 July 2014]
   Google Scholar
• Amer MH, Al-Sarraf M, Baker LH, et al. Malignant melanoma and central nervous system metastases—incidence, diagnosis, treatment and survival. Cancer 1978;42:660-8
   PubMed Web of Science ®Google Scholar
• Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011;117:1687-96
   PubMed Web of Science ®Google Scholar
• Fife KM, Coleman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004;22:1293-300
   PubMed Web of Science ®Google Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13:459-65
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm, phase 2 trial. Lancet Oncol 2012;13:879-86
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol 2014;32:abstract LBA9008
   Google Scholar
• Kelderman S, Heemskerk B, van Tinteren H, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014;63:449-58
   PubMed Web of Science ®Google Scholar
• Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-75
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Du Four S, Vandenbroucke F, et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013;36:215-22
   PubMed Web of Science ®Google Scholar
• Simeone E, Gentilcore G, Giannarelli D, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014;63:675-83
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhou J, Dong Z, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014;2:127-32
   PubMed Web of Science ®Google Scholar
• Ng Tang D, Shen Y, Sun J, et al. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamics biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013;1:229-34
   PubMed Web of Science ®Google Scholar
• Yuan J, Adamow M, Ginsberg BA, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011;108:16723-8
   PubMed Web of Science ®Google Scholar
• Kitano S, Postow MA, Ziegler CG, et al. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res 2014;2(8):812-21
   PubMed Web of Science ®Google Scholar
• Sim GC, Martin-Orozco N, Jin L, et al. IL-2 therapy promotes suppressive ICOS+ Tregs expansion in melanoma patients. J Clin Invest 2014;124:99-110
   PubMed Web of Science ®Google Scholar
• Proleukin® (Aldesleukin) US prescribing information 2012.Prometheus Laboratories, Inc., San Diego, CA. Available from: www.proleukin.com/assets/proleukin.pdf [Last Accessed 06 April 2014]
   Google Scholar
• Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment if cutaneous melanoma. Nat Rev Clin Oncol 2013;10:588-98
   PubMed Web of Science ®Google Scholar
• Joseph RW, Eckel-Passow JE, Sharma R, et al. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother 2012;35:711-15
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7
   PubMed Web of Science ®Google Scholar
• Smith FO, Goff SL, Klapper JA, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother 2007;30:130
   PubMed Web of Science ®Google Scholar
• Heimann DM, Schwartzentruber DJ. Gastrointestinal perforations associated with interleukin-2 administration. J Immunother 2001;24:287-93
   PubMedGoogle Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study. Lancet Oncol 2014;15(3):323-32
   PubMed Web of Science ®Google Scholar
• Fisher R, Ali Z, Edmonds K, et al. Clinical behavior of metastatic melanoma after progression on vemurafenib. Pigment Cell Melanoma Res 2012;25:856
   Google Scholar
• Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014;120(11):1695-701
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sileni VC, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 2014;32:144-9
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012;18:1386-94
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-31
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-6
   PubMed Web of Science ®Google Scholar
• Puzanov I, Callahan MK, Linette GP, et al. Phase 1 study of the BRAF inhibitor dabrafenib with or without the MEK inhibitor trametinib in combination with ipilimumab for V600E/K mutation-positive unresectable or metastatic melanoma [abstract 2511]. Presented at: ASCO Annual Meeting 2014; 30 May – 3 June 2014; Chicago, Illinois. Available from: http://meetinglibrary.asco.org/content/94818?media=vm
   Google Scholar
• Walker LS. Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun 2013;45:49-57
   PubMed Web of Science ®Google Scholar
• Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-47
   PubMed Web of Science ®Google Scholar
• Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 2011;84:409-21
   PubMedGoogle Scholar
• Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19:1021-34
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33
   PubMed Web of Science ®Google Scholar
• Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation status of nivolumab and ipilimumab concurrent therapy in advanced melanoma. J Clin Oncol 2014;32:abstract LBA9003
   Google Scholar
• Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte –associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-66
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lee SJ, McDermott DF, et al. Multicenter, randomized phase II trial of GM-CSF plus ipilimumab versus ipilimumab alone in metastatic melanoma: E1608 [Abstract CRA9007]. Presented at: ASCO Annual Meeting 2013; 31 May – 4 June 2013; Chicago, Illinois. Available from: http://meetinglibrary.asco.org/content/80823?media=vm
   Google Scholar
• Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014;2:632-42
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925-31
   PubMed Web of Science ®Google Scholar
• Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 2014;88:986-97
   PubMed Web of Science ®Google Scholar